Fosters Research
No Result
View All Result
No Result
View All Result
Fosters Research
No Result
View All Result
Home Industry

Is Heska Corporation (NASDAQ:HSKA) being unfairly punished by investors?

January 11, 2023
in Industry

In yesterday’s Wall Street session, Heska Corporation (NASDAQ:HSKA) shares traded at $73.37, up 9.00% from the previous session.

6 analysts cover Heska Corporation (NASDAQ:HSKA), according to research data. The consensus rating among analysts is ‘Overweight’. As we calculate the median target price by taking the range between a high of $165.00 and a low of $58.00, we find $119.00. Given the previous closing price of $67.31, this indicates a potential upside of 76.79 percent. HSKA stock price is now 12.27% away from the 50-day moving average and -17.26% away from the 200-day moving average. The market capitalization of the company currently stands at $799.00M.

Will You Miss Out On This Growth Stock Boom?

A new megatrend in the fintech market is well underway. Mobile payments are projected to boom into a massive $12 trillion market by 2028. According to Motley Fool this growth stock could "deliver huge returns." Not only in the immediate future but also over the next decade. Especially since the man behind this company is a serial entrepreneur who has been wildly successful over the years.

And this is just one of our 5 Best Growth Stocks To Own For 2023.

Sponsored

The stock has received a hold rating from 2 analysts and a buy rating from 3. Brokers who have rated the stock have averaged $107.40 as their price target over the next twelve months.

With the price target maintained at $58, Morgan Stanley recently Downgraded its rating from Equal-Weight to Underweight for Heska Corporation (NASDAQ: HSKA). , while ‘Morgan Stanley’ rates the stock as ‘Equal-Weight’.

In other news, Wilson Kevin S., CEO and President bought 11,018 shares of the company’s stock on Jan 06. The stock was bought for $645,926 at an average price of $58.62. Upon completion of the transaction, the CEO and President now directly owns 167,072 shares in the company, valued at $12.26 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Dec 22, CEO and President Wilson Kevin S. bought 3,440 shares of the business’s stock. A total of $205,152 was incurred on buying the stock at an average price of $59.64. This leaves the insider owning 156,054 shares of the company worth $11.45 million. Insiders disposed of 23,688 shares of company stock worth roughly $1.74 million over the past 1 year. A total of 0.80% of the company’s stock is owned by insiders.

There have been several recent changes in the stakes of large investors in HSKA stock. A new stake in Heska Corporation shares was purchased by TIMESSQUARE CAPITAL MANAGEMENT, LLC during the first quarter worth $17,631,000. GRANITE INVESTMENT PARTNERS, LLC invested $4,086,000 in shares of HSKA during the first quarter. In the first quarter, RICE HALL JAMES & ASSOCIATES, LLC acquired a new stake in Heska Corporation valued at approximately $3,367,000. MARSHALL WACE, LLP acquired a new stake in HSKA for approximately $2,303,000. MEROS INVESTMENT MANAGEMENT, LP purchased a new stake in HSKA valued at around $1,399,000 in the second quarter. In total, there are 248 active investors with 99.50% ownership of the company’s stock.

On Tuesday morning Heska Corporation (NASDAQ: HSKA) stock kicked off with the opening price of $69.04. During the past 12 months, Heska Corporation has had a low of $57.83 and a high of $164.57. As of last week, the company has a debt-to-equity ratio of 0.24, a current ratio of 7.20, and a quick ratio of 5.60. The fifty day moving average price for HSKA is $65.43 and a two-hundred day moving average price translates $88.36 for the stock.

The latest earnings results from Heska Corporation (NASDAQ: HSKA) was released for Jun, 2022. According to the Diagnostics & Research Company, earnings per share came in at -$0.51, missing analysts’ expectations of -$0.1 by -0.41. This compares to -$0.19 EPS in the same period last year. The net profit margin was -6.30% and return on equity was -3.80% for HSKA. The company reported revenue of $61.49 million for the quarter, compared to $60.24 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 2.08 percent. For the current quarter, analysts expect HSKA to generate $68.1M in revenue.

Heska Corporation(HSKA) Company Profile

Heska Corporation sells veterinary and animal health diagnostic and specialty products for canine and feline healthcare markets in the United States, Canada, Mexico, Australia, France, Germany, Italy, Malaysia, Spain, and Switzerland. The company offers Element DC, Element DCX, Element DC5x veterinary chemistry analyzers for blood chemistry and electrolyte analysis; Element RC, Element RCX, and Element RC3X chemistry systems for blood chemistry and electrolyte analysis; Element HT5 and scil Vet abc Plus veterinary hematology analyzers to measure blood cell and platelet count, and hemoglobin levels; Element POC blood gas and electrolyte analyzers; Element i immunodiagnostic analyzers; and Element COAG and Element AIM veterinary analyzers. It also provides HeskaView Telecytology that provides in-clinic automated microscopic slide scanning and computing equipment; IV infusion pumps; digital radiography hardware and mobile digital radiography products; ultrasound systems; Cloudbank, a Web-based image storage solution; point-of-care products to detect antigens and antibodies associated with infectious and parasitic diseases of animals; Tri-Heart Plus chewable tablets for the treatment of canine heartworm infection, and ascarid and hookworm infections; and allergy products and services, including ALLERCEPT definitive allergen panels, and therapy shots or drops. In addition, the company provides a line of bovine vaccines; biological and pharmaceutical products to other animal health companies; and turnkey services comprising research, licensing, production, labeling, and packaging; and validation support and distribution services. It sells its products to veterinarians through a telephone sales force, and third-party distributors; and trade shows, print advertising, and other distribution relationships. The company was formerly known as Paravax, Inc. and changed its name to Heska Corporation in 1995. The company was founded in 1988 and is based in Loveland, Colorado.

Tags: Heska CorporationHSKAHSKA stockNASDAQ:HSKA

Related Posts

Can Titan Pharmaceuticals Inc. (TTNP) stock recover despite sales dropping?

January 27, 2023

Investor Insight: OneWater Marine Inc. (ONEW) Goes Ballistic – Investor Confidence on the Rise

January 27, 2023

When is the right time to cash out of Matthews International Corporation [MATW] stock?

January 27, 2023

Is Atreca Inc. [BCEL] a good investment? Don’t be fooled by its recent momentum

January 27, 2023

The most important numbers to know about Ascent Solar Technologies Inc. (NASDAQ:ASTI)

January 27, 2023

Before You Invest In Harte Hanks Inc. (NASDAQ:HHS), Consider This Metric

January 27, 2023
Next Post

Do futuristic bulls still own Perdoceo Education Corporation [PRDO] stock?

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Recommended

There is little time left for Citi Trends Inc. (CTRN) to reach its 1-year target estimate. How soon will it surpass it?

3 months ago

Can Live Oak Bancshares Inc. (LOB) stock recover despite sales dropping?

3 months ago

There’s Something Awry at Ebix Inc. (NASDAQ:EBIX) Since Share Price Gets Ahead of Fundamentals

2 months ago

Reasons why Alpha and Omega Semiconductor Limited’s (NASDAQ:AOSL) fundamentals are futile

3 months ago
logo

Welcome to Fosters Research.
We provide quality information for free in a convenient place and format. You do not need to look for us – the news portal “Fosters Research” meets the reader every morning.

Categories

  • Analyst Opinions
  • Featured
  • Finance
  • Market News
  • Technical Indicators
  • Trending Stocks

Company

  • Home
  • About us
  • Contact

Recent Posts

  • Can Titan Pharmaceuticals Inc. (TTNP) stock recover despite sales dropping?
  • There is little time left for S&T Bancorp Inc. (STBA) to reach its 1-year target estimate. How soon will it surpass it?

Copyright © 2022 fostersresearch

No Result
View All Result
  • Home
  • Analyst Opinions
  • Market News
  • Technical Indicators
  • Trending Stocks

Copyright © 2022 fostersresearch